High Tech Pharm Past Earnings Performance
Past criteria checks 5/6
High Tech Pharm has been growing earnings at an average annual rate of 68.6%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 7% per year. High Tech Pharm's return on equity is 11.9%, and it has net margins of 16.2%.
Key information
68.6%
Earnings growth rate
72.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 7.0% |
| Return on equity | 11.9% |
| Net Margin | 16.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
A Look At The Intrinsic Value Of High Tech Pharm Co., Ltd. (KOSDAQ:106190)
Oct 23
Is High Tech Pharm (KOSDAQ:106190) Using Too Much Debt?
Aug 06Subdued Growth No Barrier To High Tech Pharm Co., Ltd. (KOSDAQ:106190) With Shares Advancing 25%
Jul 02There's Reason For Concern Over High Tech Pharm Co., Ltd.'s (KOSDAQ:106190) Massive 25% Price Jump
May 09Is High Tech Pharm (KOSDAQ:106190) A Risky Investment?
Apr 23We Think High Tech Pharm (KOSDAQ:106190) Has A Fair Chunk Of Debt
Feb 23Did High Tech Pharm's (KOSDAQ:106190) Share Price Deserve to Gain 91%?
Jan 19What Is The Ownership Structure Like For High Tech Pharm Co., Ltd. (KOSDAQ:106190)?
Dec 15Revenue & Expenses Breakdown
How High Tech Pharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 83,502 | 13,522 | 3,120 | 0 |
| 31 Mar 24 | 82,545 | 11,596 | 2,714 | 0 |
| 31 Dec 23 | 76,772 | 8,076 | 2,601 | 0 |
| 30 Sep 23 | 79,175 | 8,114 | 1,993 | 0 |
| 30 Jun 23 | 94,102 | 7,931 | 2,315 | 0 |
| 31 Mar 23 | 102,150 | 6,799 | 2,568 | 0 |
| 31 Dec 22 | 102,947 | 5,873 | 2,705 | 0 |
| 30 Sep 22 | 88,688 | 5 | 3,337 | 0 |
| 30 Jun 22 | 70,212 | -1,205 | 3,109 | 0 |
| 31 Mar 22 | 67,869 | -2,977 | 3,317 | 0 |
| 31 Dec 21 | 73,287 | -1,225 | 3,310 | 0 |
| 30 Sep 21 | 79,120 | -1,054 | 4,515 | 0 |
| 30 Jun 21 | 85,343 | -367 | 4,977 | 0 |
| 31 Mar 21 | 79,496 | -2,535 | 4,727 | 0 |
| 31 Dec 20 | 74,462 | -3,152 | 4,551 | 0 |
| 30 Sep 20 | 72,142 | -5,630 | 3,182 | 0 |
| 30 Jun 20 | 73,147 | -7,340 | 2,647 | 0 |
| 31 Mar 20 | 67,977 | -4,743 | 2,397 | 0 |
| 31 Dec 19 | 63,068 | -4,218 | 2,330 | 0 |
| 30 Sep 19 | 61,495 | -917 | 2,595 | 0 |
| 30 Jun 19 | 54,381 | 1,116 | 2,569 | 0 |
| 31 Mar 19 | 60,013 | 2,413 | 2,592 | -45 |
| 31 Dec 18 | 66,388 | 2,608 | 2,537 | 0 |
| 30 Sep 18 | 69,853 | 2,711 | 2,143 | 0 |
| 30 Jun 18 | 70,430 | 2,863 | 1,972 | -16 |
| 31 Mar 18 | 67,593 | 2,640 | 1,928 | 1 |
| 31 Dec 17 | 66,050 | 2,100 | 2,029 | 101 |
| 30 Sep 17 | 65,534 | 4,866 | 2,261 | 120 |
| 30 Jun 17 | 58,847 | 3,514 | 2,303 | 136 |
| 31 Mar 17 | 54,081 | 4,449 | 2,103 | 164 |
| 31 Dec 16 | 54,836 | 5,280 | 1,991 | 19 |
| 30 Sep 16 | 50,660 | 3,024 | 1,815 | 60 |
| 30 Jun 16 | 53,373 | 5,400 | 1,664 | 55 |
| 31 Mar 16 | 53,452 | 6,263 | 1,724 | 66 |
| 31 Dec 15 | 48,092 | 6,544 | 1,664 | 80 |
| 30 Sep 15 | 47,604 | 8,613 | 1,807 | 45 |
| 30 Jun 15 | 45,844 | 9,079 | 1,946 | 50 |
| 31 Mar 15 | 49,264 | 7,038 | 2,299 | 40 |
| 31 Dec 14 | 56,897 | 7,835 | 2,618 | 25 |
| 30 Sep 14 | 58,740 | 6,651 | 3,084 | 0 |
| 30 Jun 14 | 64,722 | 5,597 | 3,247 | 0 |
| 31 Mar 14 | 68,248 | 9,260 | 3,200 | 0 |
| 31 Dec 13 | 65,183 | 10,455 | 3,115 | 0 |
Quality Earnings: A106190 has high quality earnings.
Growing Profit Margin: A106190's current net profit margins (16.2%) are higher than last year (8.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A106190's earnings have grown significantly by 68.6% per year over the past 5 years.
Accelerating Growth: A106190's earnings growth over the past year (70.5%) exceeds its 5-year average (68.6% per year).
Earnings vs Industry: A106190 earnings growth over the past year (70.5%) exceeded the Pharmaceuticals industry 21.9%.
Return on Equity
High ROE: A106190's Return on Equity (11.9%) is considered low.